Dr. Peter (Peizhi) Luo is the founder and Chief Executive Officer of Adagene, an emerging biopharmaceutical company focused on novel antibody technology and product pipeline development.  He is a serial entrepreneur passionate about innovative technology and biopharmaceutical product development.  To his work, he applies a broad multi-disciplinary approach that combines ideas and methods of experimental and computational biology, chemistry, and physics.

Previously, Peter was the Chief Technology Officer of Abmaxis Inc., a wholly owned subsidiary of Merck & Co., and Director of Biologics Technology at Merck & Co., Inc.  He was responsible for developing antibody generation and engineering technology as the discovery engine for Merck novel biologics.  Prior to the acquisition of Abmaxis by Merck in 2006, Dr. Luo was the Cofounder, Chief Technology Officer, President and a Board Director of Abmaxis Inc.  He played a crucial role in building the Abmaxis management and scientific team and in shaping its technology and business strategies. Before his work at Abmaxis, Dr. Luo was the first lead scientist at Xencor specializing in computational protein design and protein laboratory.

Dr. Luo completed his postdoctoral research in protein folding at Stanford University. He received his Ph.D. in Chemistry from The University of Chicago, M.S. degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences, and B.S. degree in applied chemistry from Peking University.